

Fabiola Atzeni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6858965/publications.pdf>

Version: 2024-02-01

221
papers

7,298
citations

57758

44
h-index

76900

74
g-index

228
all docs

228
docs citations

228
times ranked

8288
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	2.2	6
2	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	2.2	12
3	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	1.9	16
4	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128
5	Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 233-244.	3.0	17
6	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
7	Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 1029.	2.4	2
8	JAK inhibitors: special issue foreword. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 179-180.	3.0	1
9	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
10	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	5
11	IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 843-853.	3.1	4
12	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab Biosimilar). <i>Internal and Emergency Medicine</i> , 2021, 16, 149-156.	2.0	8
13	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
14	Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia. <i>Stress and Health</i> , 2021, 37, 255-262.	2.6	5
15	The effect of drugs used in rheumatology for treating SARS-CoV2 infection. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 219-228.	3.1	6
16	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5
17	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , 2021, 60, 4844-4849.	1.9	23
18	Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases. <i>Drugs in Context</i> , 2021, 10, 1-9.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199325.	2.7	18
20	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , 2021, 23, 6.	4.7	32
21	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	2.4	18
22	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	2.4	44
23	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. <i>Pain and Therapy</i> , 2021, 10, 287-314.	3.2	37
24	Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Pain and Therapy</i> , 2021, 10, 577-588.	3.2	14
25	Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain. <i>Pain Research and Management</i> , 2021, 2021, 1-7.	1.8	11
26	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	8.0	57
27	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , 2021, 60, SI25-SI36.	1.9	13
28	Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 141-153.	5.8	16
29	Behçet disease: From pathogenesis to novel therapeutic options. <i>Pharmacological Research</i> , 2021, 167, 105593.	7.1	17
30	Cannabis and Autoimmunity: Possible Mechanisms of Action. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 261-271.	5.8	14
31	Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?. <i>Frontiers in Medicine</i> , 2021, 8, 735150.	2.6	8
32	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. <i>Drugs in Context</i> , 2021, 10, 1-13.	2.2	5
33	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , 2021, 92, e2021238.	0.3	1
34	The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 72-77.	0.8	4
35	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.8	2
36	Metabolic Syndrome in Systemic Sclerosis Patients: Data from Clinical Practice. <i>Israel Medical Association Journal</i> , 2021, 23, 262-263.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 186-193.	0.8	1
38	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 3-12.	0.8	1
39	Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. <i>Israel Medical Association Journal</i> , 2021, 23, 344-349.	0.1	2
40	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 120-127.	0.8	0
41	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.8	32
42	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 120-127.	0.8	4
43	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
44	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 186-193.	0.8	29
45	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.8	0
46	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre 'real-life' cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	3.0	20
47	Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis. <i>Pharmacological Research</i> , 2020, 158, 104507.	7.1	3
48	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020, 40, 101-113.	2.5	14
49	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020, 50, 1085-1090.	0.8	75
50	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 517-524.	3.1	35
51	Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e105-e108.	2.3	4
52	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , 2020, 16, 645-660.	8.0	279
53	The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3619.	2.4	3
54	Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis. <i>Immunotherapy</i> , 2020, 12, 749-756.	2.0	9

#	ARTICLE	IF	CITATIONS
55	Comment on: Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status: reply. <i>Rheumatology</i> , 2020, 59, e81-e81.	1.9	11
56	The contribution of HERV α clone 4 α 1 and other HERV α members to the pathogenesis of rheumatic autoimmune diseases. <i>Apmis</i> , 2020, 128, 367-377.	2.0	9
57	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	5.8	32
58	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , 2020, 87, 507-508.	1.6	2
59	The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2020, 47, 1198-1203.	2.0	12
60	Concerns about the safety of anti-TNF agents when treating rheumatic diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 695-705.	2.4	11
61	Toxicological considerations in the treatment of axial spondylo-arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 663-672.	3.3	1
62	Parenchymal lung disease in adult onset Still α ™s disease: an emergent marker of disease severity α ™ characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	3.5	38
63	Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 845-867.	4.1	3
64	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. <i>BioDrugs</i> , 2020, 34, 415-422.	4.6	50
65	Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. <i>Rheumatology</i> , 2020, 59, 3042-3049.	1.9	33
66	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still α ™s disease. Analysis of the α ™multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , 2020, 15, e0235326.	2.5	31
67	<p>Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 13-21.	3.2	3
68	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 277.	2.4	44
69	Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Beh α ™s Syndrome. <i>Clinical Neurology and Neurosurgery</i> , 2020, 191, 105680.	1.4	2
70	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1227.	2.4	14
71	Imaging of diffuse idiopathic skeletal hyperostosis (DISH). <i>RMD Open</i> , 2020, 6, e001151.	3.8	28
72	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020, 161, 105206.	7.1	22

#	ARTICLE	IF	CITATIONS
73	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2020, 18, 566-579.	1.7	13
74	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 245-256.	0.8	2
75	Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 31-39.	0.8	9
76	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 53-59.	0.8	6
77	Hyperbaric oxygen therapy in fibromyalgia and the diseases involving the central nervous system. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 94-98.	0.8	3
78	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.8	2
79	Title is missing!. , 2020, 15, e0235326.		0
80	Title is missing!. , 2020, 15, e0235326.		0
81	Title is missing!. , 2020, 15, e0235326.		0
82	Title is missing!. , 2020, 15, e0235326.		0
83	The therapeutic journey of biologic agents: There will be an end?. <i>Pharmacological Research</i> , 2019, 147, 104340.	7.1	3
84	Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. <i>Future Science OA</i> , 2019, 5, FSO396.	1.9	9
85	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019, 18, 102398.	5.8	75
86	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
87	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102401.	5.8	7
88	Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?. <i>Cytokine and Growth Factor Reviews</i> , 2019, 49, 42-58.	7.2	2
89	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational CIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	3.5	40
90	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1019-1032.	3.0	20

#	ARTICLE	IF	CITATIONS
91	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , 2019, 148, 104394.	7.1	16
92	Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. <i>Pharmacological Research</i> , 2019, 149, 104402.	7.1	41
93	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1755-1766.	1.9	201
94	Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study. <i>Clinical Rheumatology</i> , 2019, 38, 2541-2546.	2.2	6
95	Severe bitter taste associated with apremilast. <i>Dermatologic Therapy</i> , 2019, 32, e12876.	1.7	6
96	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019, 18, 583-592.	5.8	64
97	AB1106...PREVALENCE AND EPIDEMIOLOGY OF FAMILIAL MEDITERRANEAN FEVER AND TUMOR NECROSIS FACTORRECEPTOR-ASSOCIATED PERIODIC SYNDROME: RESULTS FROM AN ITALIAN CENTER. , 2019, , .		0
98	Microbial Agents as Putative Inducers of B Cell Lymphoma in Sjögren's Syndrome through an Impaired Epigenetic Control: The State-of-The-Art. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	2.2	9
99	Evaluation of salivary and plasma microRNA expression in patients with Sjögren's syndrome, and correlations with clinical and ultrasonographic outcomes. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 70-77.	0.8	2
100	One year in review 2019: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 3-10.	0.8	9
101	Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 63-69.	0.8	3
102	Neuromuscular efficiency in fibromyalgia is improved by hyperbaric oxygen therapy: looking inside muscles by means of surface electromyography. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 75-80.	0.8	1
103	Rate of serious infections in spondyloarthritis patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 649-655.	0.8	10
104	Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 125-132.	0.8	2
105	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 97-106.	0.8	6
106	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the <sc>LORHEN</sc> registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 422-430.	1.9	22
107	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
108	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018, 17, 24-28.	5.8	39

#	ARTICLE	IF	CITATIONS
109	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , 2018, 17, 33-35.	5.8	40
110	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 69-82.	3.0	64
111	Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 500-510.	3.3	37
112	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018, 57, vii11-vii22.	1.9	17
113	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. <i>Drug Safety</i> , 2018, 41, 1013-1022.	3.2	38
114	Neurobiological similarities between RA and fibromyalgia. <i>Nature Reviews Rheumatology</i> , 2018, 14, 324-325.	8.0	0
115	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 945-956.	3.0	16
116	Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. <i>Journal of Medical Case Reports</i> , 2018, 12, 154.	0.8	16
117	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018, 57, 1982-1990.	1.9	26
118	Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 26.	2.6	7
119	From autoinflammation to autoimmunity: old and recent findings. <i>Clinical Rheumatology</i> , 2018, 37, 2305-2321.	2.2	39
120	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 617-623.	2.8	4
121	A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. <i>Pain and Therapy</i> , 2018, 7, 163-177.	3.2	37
122	Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance. <i>Current Rheumatology Reviews</i> , 2018, 14, 131-139.	0.8	7
123	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
124	Usefulness of six-minute walk test in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 161-167.	0.8	6
125	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e54-e54.	0.9	33
126	Infections in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 323-330.	4.3	34

#	ARTICLE	IF	CITATIONS
127	Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2017, 69, 1407-1413.	3.4	26
128	Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia. <i>Arthritis and Rheumatology</i> , 2017, 69, 2144-2150.	5.6	59
129	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	1.6	15
130	Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. <i>RMD Open</i> , 2017, 3, rmdopen-2017-000472.	3.8	84
131	Rheumatic diseases and autoimmune vascular dementia. <i>Autoimmunity Reviews</i> , 2017, 16, 1265-1269.	5.8	12
132	An update on emerging drugs for fibromyalgia treatment. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 357-367.	2.4	11
133	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 127-131.	0.8	2
134	Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. <i>Journal of Pain Research</i> , 2016, 9, 279.	2.0	26
135	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 53.	3.2	17
136	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
137	Novel pharmaceutical options for treating fibromyalgia. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 559-565.	3.1	6
138	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016, 43, 869-874.	2.0	49
139	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	5.8	25
140	Pain in systemic inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 42-52.	3.3	25
141	Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2015, 17, 365.	3.5	16
142	A possible link between ankylosing spondylitis and periodontitis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2015, 54, 500-510.	1.9	16
143	<i>Helicobacter pylori</i> Infection and Gastric Autoimmunity. , 2015, , 495-503.		0
144	The impact of pain on systemic rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 1-5.	3.3	12

#	ARTICLE	IF	CITATIONS
145	How to measure chronic pain: New concepts. Best Practice and Research in Clinical Rheumatology, 2015, 29, 164-186.	3.3	22
146	Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. BMC Medical Education, 2015, 15, 89.	2.4	9
147	Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. Immunotherapy, 2015, 7, 353-361.	2.0	35
148	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 79-81.	2.2	9
149	The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. Arthritis and Rheumatology, 2015, 67, 568-575.	5.6	323
150	Doctorsâ€™ Insights into the Patient Perspective: A Qualitative Study in the Field of Chronic Pain. BioMed Research International, 2014, 2014, 1-6.	1.9	20
151	Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry. BioMed Research International, 2014, 2014, 1-8.	1.9	8
152	Rheumatic manifestations in inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 20-23.	5.8	61
153	Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatology International, 2014, 34, 1103-1110.	3.0	99
154	Autoimmunity and the Newer Biopharmaceuticals. , 2014, , 795-802.		1
155	Is atherosclerosis an autoimmune disease?. BMC Medicine, 2014, 12, 47.	5.5	122
156	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine, 2014, 81, 37-40.	1.6	23
157	New biological treatments for psoriatic arthritis. Israel Medical Association Journal, 2014, 16, 643-5.	0.1	4
158	Different effects of biological drugs in rheumatoid arthritis. Autoimmunity Reviews, 2013, 12, 575-579.	5.8	76
159	Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmunity Reviews, 2013, 12, 1115-1117.	5.8	30
160	Infections during treatment with biological agents and possible treatment in clinical practice. Expert Review of Clinical Immunology, 2013, 9, 193-195.	3.0	2
161	Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. Arthritis Care and Research, 2013, 65, 274-280.	3.4	40
162	Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmunity Reviews, 2013, 12, 703-708.	5.8	167

#	ARTICLE	IF	CITATIONS
163	Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 649-657.	3.0	41
164	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2013, 7, 69.	3.2	31
165	Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 731-8.	0.8	18
166	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012, 51, 2141-2145.	1.9	12
167	Why wait? Explaining delays in seeking therapy for early arthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 190-191.	8.0	4
168	Longterm Retention of Tumor Necrosis Factor- $\hat{\pm}$ Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	2.0	87
169	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
170	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. <i>Journal of Rheumatology</i> , 2012, 39, 849-855.	2.0	94
171	The Effect of Tumor Necrosis Factor- $\hat{\pm}$ Antagonists on Arterial Stiffness in Rheumatoid Arthritis: A Literature Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 1-8.	3.4	42
172	Twelve yearsâ€™ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 213-222.	3.0	8
173	Is fibromyalgia a discrete entity?. <i>Autoimmunity Reviews</i> , 2012, 11, 585-588.	5.8	30
174	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 589-592.	5.8	31
175	Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 33-37.	0.2	12
176	Echocardiographic approach in systemic autoimmune diseases. <i>Journal of Cardiovascular Echography</i> , 2011, 21, 152-156.	0.4	0
177	Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. <i>Autoimmunity Reviews</i> , 2011, 10, 150-154.	5.8	83
178	Switching rheumatoid arthritis treatments: An update. <i>Autoimmunity Reviews</i> , 2011, 10, 397-403.	5.8	33
179	Chronic widespread pain in the spectrum of rheumatological diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 165-171.	3.3	100
180	Clinimetric evaluations of patients with chronic widespread pain. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 249-270.	3.3	18

#	ARTICLE	IF	CITATIONS
181	Multidisciplinary approach to fibromyalgia: What is the teaching?. Best Practice and Research in Clinical Rheumatology, 2011, 25, 311-319.	3.3	49
182	Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2011, 38, 1661-1664.	2.0	46
183	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Annals of the Rheumatic Diseases, 2011, 70, 712-714.	0.9	27
184	PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease. Clinical and Experimental Rheumatology, 2011, 29, S38-43.	0.8	0
185	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clinical and Experimental Rheumatology, 2011, 29, S7-14.	0.8	23
186	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. Clinical Reviews in Allergy and Immunology, 2010, 38, 90-96.	6.5	63
187	The heart in rheumatoid arthritis. Autoimmunity Reviews, 2010, 9, 414-418.	5.8	32
188	Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. Autoimmunity Reviews, 2010, 9, 801-803.	5.8	40
189	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmunity Reviews, 2010, 9, 835-839.	5.8	75
190	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmunity Reviews, 2010, 9, 845-848.	5.8	14
191	Cardiac involvement in systemic rheumatic diseases: An update. Autoimmunity Reviews, 2010, 9, 849-852.	5.8	65
192	Resistant Cases of Psoriatic Arthritis: How to Manage Them. Journal of rheumatology Supplement, The, 2009, 83, 73-75.	2.2	9
193	Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. Rheumatology, 2009, 48, 1478-1481.	1.9	130
194	TNF- α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. Annals of the New York Academy of Sciences, 2009, 1173, 837-846.	3.8	130
195	Cardiovascular involvement in systemic autoimmune diseases. Autoimmunity Reviews, 2009, 8, 281-286.	5.8	103
196	Serious infections during anti-TNF- α treatment in rheumatoid arthritis patients. Autoimmunity Reviews, 2009, 8, 266-273.	5.8	148
197	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmunity Reviews, 2009, 8, 274-280.	5.8	101
198	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmunity Reviews, 2009, 8, 431-437.	5.8	50

#	ARTICLE	IF	CITATIONS
199	Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. <i>Rheumatology</i> , 2009, 48, 834-839.	1.9	94
200	Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. <i>Arthritis Research and Therapy</i> , 2009, 11, R125.	3.5	48
201	Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. <i>World Journal of Gastroenterology</i> , 2009, 15, 2469.	3.3	19
202	Anti-cytokine antibodies for rheumatic diseases. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1204-11.	2.3	21
203	Etiology of fibromyalgia: The possible role of infection and vaccination. <i>Autoimmunity Reviews</i> , 2008, 8, 41-43.	5.8	116
204	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , 2008, 10, R51.	3.5	64
205	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: A prospective long-term follow-up. <i>Autoimmunity</i> , 2008, 41, 87-91.	2.6	9
206	Autoantibody production in patients treated with anti-TNF- α . <i>Expert Review of Clinical Immunology</i> , 2008, 4, 275-280.	3.0	40
207	Diagnosis of cardiac involvement in systemic autoimmune diseases. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 839-843.	3.0	0
208	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2007, 6, 553-558.	5.8	30
209	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2007, 6, 529-536.	5.8	50
210	Preclinical Impairment of Coronary Flow Reserve in Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 392-397.	3.8	19
211	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , 2006, 8, R3.	3.5	105
212	Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2006, 119, 700-706.	1.5	278
213	Autoimmunity and Anti-TNF- α Agents. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 559-569.	3.8	150
214	The role of echocardiographic techniques in connective tissue diseases. <i>Autoimmunity Reviews</i> , 2005, 4, 171-177.	5.8	12
215	TNF- α , rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005, 4, 153-161.	5.8	118
216	Five-Year Follow-Up by Transesophageal Echocardiographic Studies in Primary Antiphospholipid Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 574-579.	1.6	72

#	ARTICLE	IF	CITATIONS
217	Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, 759-62.	0.8	12
218	Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2002, 3, 18.	1.9	43
219	Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN- γ , and IFN- α . <i>Cellular Immunology</i> , 2002, 220, 20-29.	3.0	46
220	Onset and temporal sequencing patterns of comorbidity between lifetime major depression, panic disorder and fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
221	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2